Comparison of Immune Response Following Surgical Management of Renal Tumors
This study has been terminated.
Sponsor:
Emory University
Information provided by (Responsible Party):
Kenneth Ogan, MD, Emory University
ClinicalTrials.gov Identifier:
NCT00289146
First received: February 7, 2006
Last updated: March 29, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Examine the effects of renal surgery on the immune system.
| Condition |
|---|
|
Kidney Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Comparison of Immune Response Following Surgical Management of Renal Tumors |
Resource links provided by NLM:
Further study details as provided by Emory University:
Biospecimen Retention: Samples Without DNA
Detailed Description:
Blood samples
| Estimated Enrollment: | 50 |
| Study Start Date: | November 2005 |
| Study Completion Date: | August 2006 |
| Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
Prospective study examining the effects of different surgical procedures on immune function. This may have bearing on overall cancer specific recurrence and survival.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Patients undergoing open or laparoscopic surgeries for the treatment of kidney tumors.
Criteria
Inclusion Criteria:
- Kidney tumor patients scheduled for open or laparoscopic surgery
Exclusion Criteria:
-
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Kenneth Ogan, MD, Associate Professor, Emory University |
| ClinicalTrials.gov Identifier: | NCT00289146 History of Changes |
| Other Study ID Numbers: | IRB3 021-2005 |
| Study First Received: | February 7, 2006 |
| Last Updated: | March 29, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Emory University:
|
kidney cancer, immunology |
Additional relevant MeSH terms:
|
Carcinoma, Renal Cell Kidney Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013